These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is there anything else we could possibly need to know about COX-2 selective inhibitor drugs? Davis P; Juby A; Robertson S; Richard N J Rheumatol; 2004 May; 31(5):847-8. PubMed ID: 15124241 [No Abstract] [Full Text] [Related]
4. Treatment of rheumatic diseases in the elderly. Luggen M Geriatr Nurs; 2001; 22(3):118-9. PubMed ID: 11410761 [No Abstract] [Full Text] [Related]
8. [COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary]. MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697296 [No Abstract] [Full Text] [Related]
9. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Atkinson HG Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146 [No Abstract] [Full Text] [Related]
10. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Hawk ET; Viner JL; Umar A Prog Exp Tumor Res; 2003; 37():210-42. PubMed ID: 12795057 [No Abstract] [Full Text] [Related]
12. Cox-2 inhibitors and cardiovascular risk: the data are inconclusive, and these drugs are needed. Lipani J Cleve Clin J Med; 2001 Nov; 68(11):961-2. PubMed ID: 11718437 [No Abstract] [Full Text] [Related]
13. Introduction. The role of COX-2-specific inhibitors in clinical practice. Lipsky PE Am J Med; 2001 Feb; 110 Suppl 3A():1S-2S. PubMed ID: 11173042 [No Abstract] [Full Text] [Related]
14. Non-steroidal anti-inflammatory drugs: back to the future. Flower RJ Rheumatology (Oxford); 1999 Aug; 38(8):693-6. PubMed ID: 10501413 [No Abstract] [Full Text] [Related]
15. [Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application]. He W; Liu CF; Huang CQ Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):184-6. PubMed ID: 12390825 [TBL] [Abstract][Full Text] [Related]
16. [Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?]. Hinz B; Brune K MMW Fortschr Med; 2000 Mar; 142(11):39-40. PubMed ID: 10786088 [No Abstract] [Full Text] [Related]
17. Recommendations for the clinical use of cyclooxygenase-2-specific inhibitors. Lipsky PE Am J Med; 2001 Feb; 110 Suppl 3A():3S-5S. PubMed ID: 11173043 [No Abstract] [Full Text] [Related]
18. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors]. Hasdai D; Gottlieb S; Godbourt U; Hod H; Kaluski E Harefuah; 2002 Oct; 141(10):922-4. PubMed ID: 12420602 [No Abstract] [Full Text] [Related]